Search

• Ocular drug delivery is a field in which regular ADME tools are not useful. • Pharmacokinetics based dosing aid for ocular drug delivery is presented. • User-friendly dosing aid guides early stage design of delivery systems. • Guidance for the delivery route, dosing and formulation design is presented. Ocular drugs are usually delivered locally to the eye. Required drug loading, release rate, and ocular retention time of drug delivery systems depend on the potency, bioavailability, and clearance of the drug at the target site. Drug-loading capacity of the formulation is limited by the material properties and size constraints of the eye. The design aid described herein for ocular drug delivery systems guides the calculation of steady-state drug concentrations in the ocular compartments, taking into account drug dose, bioavailability, and clearance. The dosing rate can be adjusted to reach the target drug concentrations, thereby guiding the design of drug delivery systems for topical, intravitreal, and subconjunctival administration. The simple design aid can be used at early stages of drug development by investigators without expertise in pharmacokinetic and pharmacodynamic modeling. Successful drug delivery to ocular targets depends on ocular biology, drug properties, and formulation characteristics. A multifactorial design aid for ocular drug delivery is presented. [ABSTRACT FROM AUTHOR]

Abstract: The in vitro generation of a functional retinal pigment epithelium (RPE) for therapeutic applications requires a limitless source of RPE cells and a supporting scaffold, which improves cell survival and promotes the acquisition of the RPE phenotype. We successfully differentiated human embryonic stem cells (hESCs) toward RPE on a transplantable, biopolymer coated polyimide (PI) membrane. We studied various membrane coatings of which several lead to the generation of a tight and highly polarized epithelium having typical characteristics and functions of human RPE. The cells established a distinctive hexagonal, cobblestone morphology with strong pigmentation, expressed RPE specific genes and proteins, and phagocytosed photoreceptor outer segments (POS) after co-culture with rat retinal explants. The barrier function of hESC-derived RPE (hESC-RPE) monolayers was confirmed by transepithelial electrical resistance and permeability measurements. In conclusion, we show that the PI biomembrane is a suitable scaffold for hESC-RPE tissue engineering. [Copyright &y& Elsevier]

Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory. [ABSTRACT FROM AUTHOR]